Journey Medical Corporation announced that the FDA has accepted the Company's New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.66 USD | +20.43% | +40.40% | -2.26% |
May. 13 | Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024 | |
May. 13 | Journey Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.26% | 94.06M | |
+48.94% | 765B | |
-6.21% | 354B | |
+20.73% | 331B | |
+9.93% | 299B | |
+18.87% | 248B | |
-1.96% | 219B | |
+11.11% | 216B | |
+5.50% | 164B | |
-2.41% | 162B |
- Stock Market
- Equities
- DERM Stock
- News Journey Medical Corporation
- Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea